



European Monitoring Centre
for Drugs and Drug Addiction

PROGRAMME

Treatment demand indicator (TDI) and treatment-related data

EMCDDA TDI/Treatment annual expert meeting

20–21 September 2017
EMCDDA, Lisbon

| Aim and objectives

Venue: Conference room, EMCDDA, Lisbon

Aim: to discuss with TDI experts about annual progress in the implementation of TDI/Treatment related data

Specific objectives:

- Exchange and discuss about TDI implementation and treatment related data at European and national level
- Explore implications for practice and policy of ageing drug users
- Reflect on role of treatment-related data in mortality – linkage cohort studies
- Investigate data quality, data reporting and assessment tools
- Discuss about possible need for revision of New Psychoactive Substances coding in TDI
- Understand trends in treatment related data: consistency between data sources and methodological issues
- Discuss about findings of the project on Opioid Substitution Treatment access, quality and prevention of diversion
- Review the implementation of the TDI prevalence Project
- Share experiences on how TDI/ treatment data inform responses : the new European Responses Guide
- Present on recent developments in the field of psychiatric comorbidity
- Inform about treatment referrals from the criminal justice system

Outcome of the meeting:

- Short summary of the main findings
- Suggestion for improvement in the TDI European and national implementation
- Briefing note on trend analysis

Structure of the meeting:

The meeting will be organised in plenary sessions and in parallel workshops

Participants:

TDI/DRD experts, invited experts

Wednesday 20 September 2017

DRD/TDI meeting (Common session)

09.30	<p>Plenary Session I: Mortality cohorts among high-risk drug users — key role of treatment data Chairs: Julian Vicente and Christophe Palle</p> <p><i>Objective: to discuss examples of cohort studies and reflect on how, in practice, collaboration with treatment centres and use of treatment data, can contribute to assess the whole health impact of high-risk forms of drug use – to reflect on identifying data capable of supporting linkage.</i></p> <p>Overview of the topic — Isabelle Giraudon, EMCDDA</p> <p>The performance of a national OMT program with time. Are the benefits from the program in terms of mortality reduction stable or changing during a period from 1997–2009? — Thomas Clausen, Norway</p> <p>Linkage study TDI and mortality registers: main findings, practicalities, lessons learnt, capacity building opportunities — Tim Millar, United Kingdom</p> <p>Brief tour de table — other mortality cohorts</p>
11.00	Coffee break

11.30	<p>Conference room</p> <p>Plenary Session II: Ageing high-risk drug users Chairs: Alessandro Pirona and Catherine Crawford</p> <p><i>Objective: The joint session is dedicated to the ageing cohorts of high risk drug users in and out of treatment and the implications for practice and policy at national and European level</i></p> <p>Predicting the size and characteristics of the drug treatment population in England — Martin White, United Kingdom</p> <p>Ageing among high risk drug users in the Netherlands — Will Kuijpers and Jeroen Wisselink, the Netherlands</p> <p>Ageing among opiate users in Austria: routine data, implications, challenges — Alexander Grabenhofer-Eggerth, Austria</p> <p>Ageing among high risk drug users in Portugal — Domingos Duran, Portugal</p> <p>Treatment for opiate use and outcomes in older adults: a systematic literature review — Suzi Lyons, Ireland</p>	<p>Room 107</p> <p>Workshop with IPA: Implementation of DRD/TDI in IPA countries Chairs: Sandrine Sleiman and Cécile Martel</p> <p><i>Objective: to have a joint session with the experts of DRD and TDI on current monitoring situation in the countries</i></p> <p>Presentation of the EMCDDA IPA 6 cooperation project</p> <p>Overview of the situation for what regards drug-related deaths data collection: strengths and challenges at national level (tour de table)</p> <p>Overview of the situation for what regards drug-related treatment data collection: strengths and challenges at national level (tour de table)</p>
13.00	Lunch break	
TDI/Treatment expert meeting		
Conference room		
14.30	<p>Plenary Session III: Update on last developments in treatment related data and links with other epidemiological indicators Chairs: Linda Montanari and Anastasios Fotiou</p> <p><i>Objective: to provide an update on TDI/treatment related data implementation, to discuss recent findings, and provide an overview of last developments of key epidemiological indicators</i></p> <p>Introduction: update on TDI implementation and on-going activities — Linda Montanari, EMCDDA</p> <p>Overview of last treatment-related data — Bruno Guarita, EMCDDA</p> <p>Update on other treatment related activities (EFSQ, e-health, OST project) — Alessandro Pirona, EMCDDA</p> <p>Workbooks feedback — Alessandro Pirona, EMCDDA</p> <p>Overview on update from other key epidemiological indicators, highlight of possible complementarity with TDI (Joao Matias – GPS, Isabelle Giraudon – DRD and DRID, Thomas Seyler – PDU)</p> <p>Update on the project on misuse of tramadol — Klaudia Palczak, EMCDDA</p>	
15.30	Coffee break	
16.00	<p>Plenary Session IV: Data quality and data reporting Chairs: Sandrine Sleiman and Ioanna Yiasemi</p> <p><i>Objective: to discuss main data quality issues in TDI data and need for revising NPS codes in TDI. To present national developments in TDI</i></p> <p>Round table with update from the countries: 10 countries (2 minutes each)</p> <p>NPS coding: how to adapt monitoring to a changing context — Ana Gallegos, EMCDDA</p> <p>Main data quality issues — Bruno Guarita, EMCDDA</p> <p>Round table with update from the countries: 10 countries (2 minutes each)</p>	
18.00	Cocktail	

Thursday 21 September 2017			
Conference room			
9.00	Plenary Session V: introduction to workshops Chairs: Bruno Guarita and Claudia Ranneries <i>Objective: to present national developments in TDI and introduce parallel workshops</i> Round table with update from the countries: 10 countries (2 minutes each) Introduction to workshops		
Parallel sessions I			
09.30	<i>to discuss in small groups about practical implementation of TDI/Treatment related data</i>		
	Room 107 1. Interpreting trends: discussing trends of new heroin clients Chairs: Jelena Jankovic and Jane Mounteney Presentations: Andrew Jones (United Kingdom), Diana Vanaga (Latvia), Ieva Vaitkeviciute (Lithuania), Natalia Magliochetti (Italy) Discussant: Gordon Hay	Room 106 2. Opioid substitution treatment in Europe: access, quality and prevention of diversion Chairs: Alessandro Pirona and Barbara Braun Participating countries: France, Germany, Ireland, Czech Republic, Austria, Poland, Finland	Room 012 3. Discussing the monitoring of Minimum Quality Standards Chairs: Marica Ferri and Lubomír Okruhlica
11.00	Coffee break		
Parallel sessions II			
11.30	Room 106 1. Interpreting trends: understanding changes in reported data, including consistency between sources Chairs: Barbara Janikova and André Noor Case studies: Greece, Bulgaria, Romania, Sweden and Spain Discussant: Gordon Hay	Room 107 2. TDI Prevalence: first results and next data collection Chairs: Alexander Grabenhofer-Eggert and Linda Montanari Presentations: Wil Kuijpers/ Jeroen Wisselink (Netherlands), Diana Vanaga (Latvia), Ioanna Yiasemi (Cyprus)	Room 012 3. Psychiatric comorbidity: assessment and diagnosis Chairs: Juan Mestre Pintó and Julian Vicente
13.00	Lunch break		
14.30	Plenary Session VI: How can treatment monitoring inform responses to drug use Chairs: Julian Vicente and Anna Péterfi <i>Objective: to discuss how treatment related data can be used to identify treatment needs and service planning; to provide recent development on psychiatric comorbidity; to explore the role of criminal justice system in treatment referrals</i> Psychiatric co-morbidity: possibility of a field trial of existing instrument in some treatment centres — Marta Torrens Melich, Medical Research Institute, Barcelona Feedback from the Parallel session I		
16.00	Coffee break		
16.30	Overview of the report on Health and Social Responses to Drug Problems: a European Guide — Nicola Singleton, EMCDDA Treatment Referrals from the Criminal Justice System — Brendan Hughes, EMCDDA Feedback from the Parallel session II Conclusions: Linda Montanari		
17.30	End of the meeting		